UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HIV Drug Resistance — An Emerging Threat to Epidemic Control

The New England journal of medicine, 2017-10, Vol.377 (17), p.1605-1607

2017

Volltextzugriff (PDF)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Clinical pharmacology and therapeutics, 2022-12, Vol.112 (6), p.1191-1200

2022

Volltextzugriff (PDF)

Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV

Nature communications, 2021-07, Vol.12 (1), p.4450-4450, Article 4450

2021

Volltextzugriff (PDF)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018-04, Vol.4 (2), p.72-79

2018

Volltextzugriff (PDF)

Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance

AIDS (London), 2021-07, Vol.35 (8), p.1305-1307

2021

Volltextzugriff (PDF)

Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials

AIDS (London), 2020-12, Vol.34 (15), p.2259-2268

2020

Volltextzugriff (PDF)

Are new antiretroviral treatments increasing the risks of clinical obesity?

Journal of Virus Eradication, 2019-01, Vol.5 (1), p.41-43

2019

Volltextzugriff (PDF)

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

The Lancet (British edition), 2018-07, Vol.392 (10144), p.312-358

2018

Volltextzugriff (PDF)

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials

Current opinion in HIV & AIDS, 2018-03, Vol.13 (2), p.102-111

2018

Volltextzugriff (PDF)

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide

Current opinion in HIV & AIDS, 2017-07, Vol.12 (4), p.324-333

2017

Volltextzugriff (PDF)

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

Annals of internal medicine, 2022-05, Vol.175 (5), p.744-746

2022

Volltextzugriff (PDF)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

AIDS (London), 2019-07, Vol.33 (9), p.1455-1465

2019

Volltextzugriff (PDF)

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

The New England journal of medicine, 2006-01, Vol.354 (3), p.251-260

2006

Volltextzugriff (PDF)

Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy

Clinical infectious diseases, 2020-06, Vol.70 (12), p.2599-2606

2020

Volltextzugriff (PDF)

COVID-19 death in people with HIV: interpret cautiously

The lancet HIV, 2021-01, Vol.8 (1), p.e2-e3

2021

Volltextzugriff (PDF)

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

AIDS (London), 2017-11, Vol.31 (18), p.2503-2514

2017

Volltextzugriff (PDF)

High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya

PloS one, 2023-06, Vol.18 (6), p.e0285787-e0285787

2023

Volltextzugriff (PDF)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP

Journal of Virus Eradication, 2018-10, Vol.4 (4), p.215-224

2018

Volltextzugriff (PDF)

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Journal of Virology, 2006-05, Vol.80 (10), p.4909-4920

2006

Volltextzugriff (PDF)

Has the time come to abandon efavirenz for first-line antiretroviral therapy?

Journal of antimicrobial chemotherapy, 2014-07, Vol.69 (7), p.1742-1747

2014

Volltextzugriff (PDF)

More pressure on integrase strand-transfer inhibitors?

The lancet HIV, 2024-05, Vol.11 (5), p.e278-e280

2024

Volltextzugriff (PDF)

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

The Lancet infectious diseases, 2011-05, Vol.11 (5), p.363-371

2011

Volltextzugriff (PDF)

Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment

The Lancet infectious diseases, 2017-08, Vol.17 (8), p.882-882

2017

Volltextzugriff (PDF)

1 – 25 von 424

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(403)
Mit Volltextzugriff
(337)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(315)
Life Sciences & Biomedicine
(304)
Humans
(296)
Infectious Diseases
(248)
Hiv Infections - Drug Therapy
(179)
Male
(163)
Hiv
(161)
Female
(150)
Human Immunodeficiency Virus
(148)
Adult
(146)
Immunology
(144)
Biological And Medical Sciences
(108)
Medical Sciences
(104)
Middle Aged
(104)
Virology
(98)
Aids/hiv
(88)
Anti-Hiv Agents - Therapeutic Use
(79)
Viral Diseases
(74)
Human Viral Diseases
(73)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(69)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

HIV Drug Resistance — An Emerging Threat to Epidemic Control

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance

Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials

Are new antiretroviral treatments increasing the risks of clinical obesity?

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy

COVID-19 death in people with HIV: interpret cautiously

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Has the time come to abandon efavirenz for first-line antiretroviral therapy?

More pressure on integrase strand-transfer inhibitors?

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment

Suchergebnisse filtern